newsfilter
← Latest News
ACCESS Newswire·

Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells

TELO
  • Telomir Pharmaceuticals announced new in vitro findings showing investigational compound Telomir-1 kills aggressive human leukemia (HL60) cells with dose-dependent reduction in viable cells.
  • These results expand Telomir-1's oncology profile into blood cancers, adding to previously reported activity in triple-negative breast, pancreatic, & aggressive prostate cancer models.
  • Leukemia is defined as a blood & bone marrow cancer with over 60,000 new US cases annually, characterized by high relapse rates, treatment resistance, & toxicity from existing therapies.
  • Telomir-1 targets iron dependence & epigenetic silencing, reducing intracellular iron levels & inhibiting lysin histone demethylase (KDM) enzymes including KDM2, KDM5, & KDM6 families.
  • The compound demonstrated ability to reverse hypermethylation of tumor-suppressor genes such as STAT1, CDKN2A, & RASSF1A in prior cancer models.
  • Previous studies showed Telomir-1 caused dose-dependent loss of viability in triple-negative breast cancer & reduced survival in pancreatic cancer, both reversible by iron re-addition.
  • In vivo aggressive prostate cancer models showed reduced tumor volume & reversal of abnormal DNA methylation across multiple tumor-suppressor genes.
  • CEO Erez Aminov stated Telomir-1 aims to address dysregulated iron & abnormal DNA methylation to reset underlying biology rather than treating downstream symptoms.
  • Chief Scientific Advisor Dr. Itzchak Angel noted the potency in HL60 cells aligns with the company's framework regarding iron imbalance & epigenetic disruption.
  • Telomir Pharmaceuticals remains a preclinical-stage biotechnology company developing small-molecule therapies targeting epigenetic & metabolic roots of cancer & aging.